SynaptixBio, the only company licensed to commercialise a treatment for the rare, deadly disease H-ABC, says this must be a wake-up call for the government to act
A new survey, conducted by Rare Barometer on behalf of EURORDIS, highlights the growing gap in mental health problems between rare disease patients and the general population. 70% of those living with rare diseases, and their families, reported poor mental health.
SynaptixBio, which is developing a therapy for the rare, deadly neurological condition, H-ABC, says the figures are a stark reminder that mental health problems disproportionately affect those who are already suffering physically.
The survey, which consisted of almost 500 patients and their families across the UK, found that nearly half of the respondents suffer from moderate to severe symptoms of depression. This is six times greater than in the general population in the UK.
Dan Williams PhD, CEO at SynaptixBio, said; “Awareness of mental health issues has grown dramatically in recent years, which is very welcome, but it has placed a strain on health and social services that means long delays in accessing help.
“For those living with a rare disease, and their families, the outlook is even worse. The new survey confirms that most of them do not receive professional psychological support.”
The survey also highlighted that feelings of severe isolation are up to 20 times more common among rare disease patients than among the general public.
Dan Williams added; “Rare genetic conditions are often life-limiting and medically complex, and can take years to diagnose. This adds tremendously to the mental burden patients and their families have to carry.
“While it’s well-known that living with a rare genetic condition can negatively impact mental health, there is a additional negative feedback loop as poor mental health has a detrimental effect on physical symptoms.”
Rare Barometer is a not-for-profit survey initiative run independently by EURORDIS-Rare Diseases Europe, which advocates on behalf of rare disease patient groups and collaborates with researchers to prioritise patients’ needs.
The survey results reflect and confirm the findings from an earlier study by Rare Diseases UK that noted more than 90% of respondents felt anxious, stressed or depressed due to their rare condition, and that 36% of patients and 19% of carers had experienced suicidal thoughts.
Around 1 in 17 people will be affected by a rare disease during their lifetime. In the UK, this amounts to over 3.5 million people, but only around 5% of rare diseases have an approved treatment. The vast majority of the c10,000 known rare diseases have no effective therapy.
A piece on the NHS website adds that rare conditions can have a significant impact on mental health due to their effects on daily life. Challenges include chronic pain and fatigue, mobility issues, physical changes, and the lack of awareness around rare diseases in general, all of which contribute to an increased risk of depression, anxiety and stress in patients and their families and/or caregivers.
The NHS article also highlights the impact on families, whom it says suffer from anxiety, grief and emotional strain. Siblings may feel disoriented and neglected and their own needs may be inadvertently overlooked. Finally, the article notes, guilt is also common among families with rare conditions, noting that parents may blame themselves for passing on a genetic variant while simultaneously grappling with the overwhelming responsibility of caring for a child with complex medical needs.
Dan Williams concluded; “The government really needs to face up to this crisis. Rare diseases predominantly affect younger people, and they are typically life-limiting, so it is incumbent upon those who can effect change to do so urgently.
“The scale of the challenge shouldn’t stop us from doing whatever is possible to alleviate the strains and stresses that ultimately lead to mental health issues.”
To find out more about SynaptixBio please visit https://www.synaptixbio.com/.



























